Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
HQBagsvaerd, DK
Size (employees)42,076 (est)+2%
Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, DK
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Novo Nordisk

Lars Rebien Sørensen

Lars Rebien Sørensen

President & Chief Executive Officer
Jesper Brandgaard

Jesper Brandgaard

EVP and Chief Financial Officer
Maziar Mike Doustdar

Maziar Mike Doustdar

EVP of International Operations
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

EVP Corporate Developemnt
Show more

Novo Nordisk Office Locations

Novo Nordisk has offices in Pensacola, Knoxville, Detroit, Grand Rapids and in 137 other locations
Bagsvaerd, DK (HQ)
Novo Nordisk A/S Novo Allé
Mississauga, CA
300-2680 Skymark Avenue, Floor 3
Beijing, CN
18F, East Tower, World Financial Center, No. 1 East 3rd Ring Middle Road, Chaoyang District
Mainz, DE
Brucknerstrasse 1
Bangalore, IN
Plot No.32, 47-50, EPIP Area, Whitefield
Tokyo, JP
Meiji Yasuda Seimei Bldg. 2-1-1, Marunouchi, Chiyoda-ku
Show all (141)
Report incorrect company information

Novo Nordisk Financials and Metrics

Novo Nordisk Revenue

Market capitalization (15-Oct-2018)


Closing stock price (15-Oct-2018)

Novo Nordisk's current market capitalization is $101.8 b.
Show all financial metrics

Novo Nordisk Operating Metrics

FY, 2015FY, 2016

Patients Reached

26.80 m

Phase III Trials Products

6 3

Projects in R&D Pipeline

19 17
Show all operating metrics

Novo Nordisk Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
ZiyloAugust 20, 2018$800 m
Report incorrect company information

Novo Nordisk Online and Social Media Presence

Embed Graph
Report incorrect company information

Novo Nordisk News and Updates

Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

Novo Nordisk could close biopharma acquisition this year - CEO

COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday.

Insulin Delivery Devices 2018 Global Market Key Players - Novo Nordisk A/S, Insulet, Abbott Laboratories, Becton Dickinson, Ypsomed Holdings AG, F. Hoffmann-La Roche......

Insulin Delivery Devices – Global Market Growth, Opportunities, Analysis of Top Key Players and Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Novo Nordisk picks AstraZeneca executive to head biopharma business

Novo Nordisk has hired AstraZeneca's head of cardiovascular and metabolic diseases to head its biopharma business, which has been struggling with declining sales and a failed acquisition.

Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm

Bagsværd, Denmark, 15 October 2018 - Novo Nordisk A/S today announced the appointment of Ludovic Helfgott as executive vice president of Biopharm, effective 3 April 2019.

Novo Nordisk to establish California manufacturing site for stem cell-based therapies

Bagsværd, Denmark, Monday 1 October ­- Novo Nordisk today announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previo…
Show more
Report incorrect company information

Novo Nordisk Company Life and Culture

Report incorrect company information